The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The framework, called HEAL, could be used as an early screening test for AAA and as a personal health management tool. In addition, it may be applicable to other complex diseases.
A study of more than 5,000 breast cancer patients found that multi-gene sequencing has rapidly replaced BRCA1/2-only tests, resulting in better pathogenic variant detection but also higher VUS rates.
A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.
The researchers said that their reagent, which makes TB cells emit light, could be integrated into slide-and-microscope testing platforms.
As a clinical study seeks to decide whether low levels of PCT can guide antibiotic therapy, researchers are exploring alternate, gene expression biomarkers.
A test being developed by researchers at Stanford University and Enable Biosciences could be used for HIV screening sooner than traditional immunoassays.
Its CEO said that although a hospital screening test for sepsis is a focus, a fever test that informs about antibiotic use could be available sooner.
The funding will support further development of an existing serum-based assay and expansion of the test to use saliva samples.